# Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System

Source: https://onco.cc/trials/nct03067051/  
OnCo record `nct03067051` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Verteporfin in prostate cancer, run by SpectraCure AB, now recruiting.

## Summary

Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System is a phase 1/2 interventional study registered as NCT03067051 by SpectraCure AB, with 66 participants planned, started 2017-03-21 and due to reach its primary completion in 2027-07-31. Interventions recorded: Verteporfin and SpectraCure P18 System.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03067051
- Phase: 1/2
- Setting: Open-label Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System (Interstitial Multiple Diode Lasers and IDOSE® Software) and Verteporfin for Injection (VFI) for the Treatment of Recurrent Prostate Cancer
- Sponsor: SpectraCure AB
- Enrolled: 66

## Sources

- ClinicalTrials.gov NCT03067051: https://clinicaltrials.gov/study/NCT03067051

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- companies: [SpectraCure](https://onco.cc/companies/spectracure/)

---
JSON: https://onco.cc/api/v1/entities/nct03067051.json